{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Eflornithine+%28DFMO%29", "query": { "intervention": "Eflornithine (DFMO)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 39, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Eflornithine+%28DFMO%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-26T22:39:29.739Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05500508", "title": "Oral AMXT 1501 Dicaprate in Combination With IV DFMO", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer", "Solid Tumor", "Solid Carcinoma", "Advanced Cancer", "DIPG Brain Tumor", "Ovary Cancer", "Breast Cancer", "Papillary Thyroid Cancer", "Head and Neck Cancer", "Gastric Cancer", "Nsclc", "Mesotheliomas Pleural", "Mesothelioma Peritoneum", "Esophageal Cancer", "Diffuse Midline Glioma, H3 K27M-Mutant", "Endometrial Cancer", "Cervical Cancer", "Melanoma", "Colorectal Cancer", "Glioma, Malignant" ], "interventions": [ { "name": "AMXT1501", "type": "DRUG" }, { "name": "DFMO", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aminex Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 15, "start_date": "2022-11-29", "completion_date": "2024-12-12", "has_results": false, "last_update_posted_date": "2024-12-24", "last_synced_at": "2026-09-26T22:39:29.739Z", "location_count": 6, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 3 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05500508" }, { "nct_id": "NCT02559778", "title": "Pediatric Precision Laboratory Advanced Neuroblastoma Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "Ceritinib", "type": "DRUG" }, { "name": "dasatinib", "type": "DRUG" }, { "name": "sorafenib", "type": "DRUG" }, { "name": "vorinostat", "type": "DRUG" }, { "name": "DFMO", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Giselle Sholler", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "22 Years", "sex": "ALL", "summary": "Up to 22 Years" }, "enrollment_count": 500, "start_date": "2015-09", "completion_date": "2035-09", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-09-26T22:39:29.739Z", "location_count": 24, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Oakland", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Hartford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02559778" }, { "nct_id": "NCT01059071", "title": "Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "DFMO", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Giselle Sholler", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 21, "start_date": "2010-02", "completion_date": "2015-05", "has_results": true, "last_update_posted_date": "2024-08-06", "last_synced_at": "2026-09-26T22:39:29.739Z", "location_count": 7, "location_summary": "Orange, California • Hartford, Connecticut • Orlando, Florida + 4 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Orlando", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01059071" }, { "nct_id": "NCT01349881", "title": "S0820, Adenoma and Second Primary Prevention Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Neoplasms" ], "interventions": [ { "name": "Eflornithine placebo & sulindac placebo", "type": "DRUG" }, { "name": "eflornithine & sulindac placebo", "type": "DRUG" }, { "name": "Eflornithine placebo & sulindac", "type": "DRUG" }, { "name": "Eflornithine plus sulindac", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 354, "start_date": "2013-08-23", "completion_date": "2032-02-01", "has_results": false, "last_update_posted_date": "2026-04-02", "last_synced_at": "2026-09-26T22:39:29.739Z", "location_count": 990, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 617 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01349881" }, { "nct_id": "NCT04696029", "title": "DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Medulloblastoma" ], "interventions": [ { "name": "Difluoromethylornithine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Giselle Sholler", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 118, "start_date": "2021-03-29", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-09-26T22:39:29.739Z", "location_count": 25, "location_summary": "Little Rock, Arkansas • Oakland, California • Sacramento, California + 22 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Oakland", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04696029" }, { "nct_id": "NCT07287917", "title": "Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma (Skin Cancer)", "HER2-low Hormone Receptor Positive Breast Cancer" ], "interventions": [ { "name": "AMXT 1501 Dicaprate", "type": "DRUG" }, { "name": "DFMO", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Capivasertib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aminex Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 92, "start_date": "2026-01-26", "completion_date": "2028-12-29", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-09-26T22:39:29.739Z", "location_count": 20, "location_summary": "Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Englewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07287917" }, { "nct_id": "NCT05879367", "title": "Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma, IDH-wildtype", "Glioblastoma", "Glioblastoma Multiforme", "Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype", "GBM", "Astrocytoma", "Astrocytoma, IDH-Mutant" ], "interventions": [ { "name": "Eflornithine (Dose Level -1)", "type": "DRUG" }, { "name": "Eflornithine (Dose Level 2)", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Orbus Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2023-07-24", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2025-06-25", "last_synced_at": "2026-09-26T22:39:29.739Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Detroit, Michigan • New York, New York + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05879367" }, { "nct_id": "NCT03536728", "title": "Oral AMXT 1501 Dicaprate in Combination With DFMO", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "Solid Tumor", "Solid Carcinoma", "Advanced Cancer" ], "interventions": [ { "name": "AMXT1501", "type": "DRUG" }, { "name": "DFMO", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aminex Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 56, "start_date": "2018-06-12", "completion_date": "2023-04-21", "has_results": false, "last_update_posted_date": "2023-05-25", "last_synced_at": "2026-09-26T22:39:29.739Z", "location_count": 4, "location_summary": "Austin, Texas • Houston, Texas • San Antonio, Texas + 1 more", "locations": [ { "city": "Austin", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03536728" }, { "nct_id": "NCT02395666", "title": "Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "DFMO", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Giselle Sholler", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 140, "start_date": "2015-03-05", "completion_date": "2023-08-24", "has_results": true, "last_update_posted_date": "2024-08-06", "last_synced_at": "2026-09-26T22:39:29.739Z", "location_count": 22, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Diego", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02395666" }, { "nct_id": "NCT01483144", "title": "Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Familial Adenomatous Polyposis" ], "interventions": [ { "name": "Eflornithine", "type": "DRUG" }, { "name": "Eflornithine Placebo", "type": "DRUG" }, { "name": "Sulindac 150 MG", "type": "DRUG" }, { "name": "Sulindac placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cancer Prevention Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 171, "start_date": "2013-10", "completion_date": "2019-03", "has_results": true, "last_update_posted_date": "2021-06-08", "last_synced_at": "2026-09-26T22:39:29.739Z", "location_count": 10, "location_summary": "La Jolla, California • Atlanta, Georgia • Boston, Massachusetts + 7 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01483144" } ] }